# A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer

> **NCT07371871** · NA · NOT_YET_RECRUITING · sponsor: **Anhui Provincial Cancer Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Gastric Cancer

## Interventions

- **DRUG:** Trifluridine/Tipiracil (TAS-102) combined with Apatinib

## Key facts

- **NCT ID:** NCT07371871
- **Lead sponsor:** Anhui Provincial Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-08
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07371871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07371871, "A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07371871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*